



HCC BREAST CANCER PROGRAM RESEARCH RETREAT

October 9, 2026 | 11:15AM - 6:00PM

Massachusetts General Hospital, O'Keefe Auditorium (Blake 160)
55 Fruit St, Boston, MA 02114

11:15AM – 12:00PM HCC Pathfinder Trainee Session (Separate Registration Required)

WELCOME

12:00 – 12:25PM Lunch

12:25 – 12:30PM Welcome and Introductions

SESSION I

12:30 – 12:45PM ***New technologies for ultrasensitive ctDNA detection***

Q&A 12:45 – 12:55PM Viktor Adalsteinsson, PhD | Director, Gerstner Center for Cancer Diagnostics, Broad Institute

12:55 – 1:25PM ***Keynote Lecture: Advancing Precision Oncology with ctDNA in Breast Cancer***

Q&A 1:25 – 1:40PM

Pedram Razavi, MD, PhD | Assistant Attending, Department of Medicine; Director, Breast Translational Program and Breast Molecular Tumor Board; Director, Liquid Biopsy and Cancer Genomics, Biomarker Development Program; Director, Translational Oncology Partnership Program; Memorial Sloan Kettering Cancer Center

1:40 – 2:10PM ***Applications of epigenomic liquid biopsy in breast oncology and beyond***

Q&A 2:10 – 2:20PM

Sylvan Baca, MD, PhD | Assistant Professor of Medicine Harvard Medical School, Dana Farber Cancer Institute

2:20 – 2:35PM Break

SESSION II

* HCC Pathfinder Program Travel Awardees

2:35 – 2:40PM Introduction

Lee Nadler, MD | Multiple Principal Investigator, Harvard Catalyst; Virginia and D.K. Ludwig Professor for Cancer Research and Teaching at Harvard Medical School

2:40 – 2:46PM ***Timing the onset of homologous recombination deficiency before breast cancer diagnosis***

Michail Andreopoulos, MPhil | PhD Student, Harvard Medical School

2:46 – 2:52PM	<i>Therapeutic strategies involving selective CDK2 inhibitors in RB-proficient and RB- deficient HR-positive metastatic breast cancer</i> Kazi Islam, PhD Postdoctoral Fellow, Massachusetts General Hospital
2:52 – 2:58PM	<i>Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)</i> Maxwell Lloyd, MD* Instructor, Massachusetts General Hospital
2:58 – 3:04PM	<i>Mechanistic interpretation of cfDNA fragmentation topography through joint deconvolution of fragmentation processes and tissue composition with cfVista</i> Allen Lynch, BS* PhD Student, Harvard Medical School
3:04 – 3:10PM	<i>Beyond ctDNA: Ultrasensitive Protein Liquid Biopsy to Refine Breast Cancer Screening and Diagnostic Workflows</i> Justin Rolando, PhD* Instructor, Brigham and Women's Hospital
3:10 – 3:16PM	<i>Clinicogenomic characterization and ctDNA detection of ESR1 fusion positive metastatic breast cancer</i> Katheryn Santos, BS* Postbaccalaureate Fellow, Dana-Farber Cancer Institute
3:16 – 3:22PM	<i>Cell-free DNA Methylation Deconvolution for Liquid Biopsy in Breast Cancer and Other Solid Tumors</i> Ze Zhang, PhD Postdoctoral Fellow, Dana-Farber Cancer Institute
3:22 – 3:40PM	Panel Discussion
SESSION III	
3:40 – 4:10PM Q&A 4:10 – 4:25PM	<i>Keynote Lecture: Molecular Residual Disease in Early Breast Cancer: Bridging Detection and Intervention</i> Heather Parsons, MD, MPH Maudslien Endowed Chair in Breast Cancer Precision Oncology Research; Program Head, Breast Oncology; Associate Professor, Clinical Research Division, Fred Hutch Cancer Center; Associate Professor, Department of Medicine, University of Washington
4:25 – 5:10PM	Molecular Tumor Board Heather Parsons, MD, MPH; Arielle Medford, MD; Stefania Morganti, MD; Ilana Schlam, MD, MPH
CONCLUSION	
5:10 – 5:15PM	Closing Remarks
5:15 – 6:00PM	Social Hour